{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+First+Intervention+%283+weeks%29&page=4", "query": { "intervention": "Placebo Comparator: First Intervention (3 weeks)", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 111, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+First+Intervention+%283+weeks%29&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+First+Intervention+%283+weeks%29&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T16:14:55.220Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00203996", "title": "Polycystic Ovary Syndrome (PCOS) and Sleep Apnea", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Polycystic Ovary Syndrome", "Obstructive Sleep Apnea" ], "interventions": [ { "name": "continuous positive airway pressure (CPAP)", "type": "DEVICE" }, { "name": "depot leuprolide plus estrogen/progestin replacement", "type": "DRUG" }, { "name": "pioglitazone", "type": "DRUG" }, { "name": "REM frag", "type": "PROCEDURE" }, { "name": "SWS supp", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "DRUG", "PROCEDURE" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 37, "start_date": "2003-09", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2023-03-21", "last_synced_at": "2026-10-11T16:14:55.220Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00203996" }, { "nct_id": "NCT02522988", "title": "The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fatigue" ], "interventions": [ { "name": "Open-label placebo intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 74, "start_date": "2015-06", "completion_date": "2021-08-01", "has_results": false, "last_update_posted_date": "2021-09-24", "last_synced_at": "2026-10-11T16:14:55.220Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02522988" }, { "nct_id": "NCT07218354", "title": "Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alcohol Use Disorder" ], "interventions": [ { "name": "Semaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 622, "start_date": "2026-07-28", "completion_date": "2030-03-30", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-11T16:14:55.220Z", "location_count": 19, "location_summary": "Long Beach, California • Palo Alto, California • West Los Angeles, California + 15 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "West Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07218354" }, { "nct_id": "NCT01656187", "title": "Attenuation of Corticosteroid Induced Hippocampal Changes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Organic Memory Impairment" ], "interventions": [ { "name": "Memantine 10 mg capsule", "type": "DRUG" }, { "name": "Memantine-matched Placebo capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 46, "start_date": "2012-01", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2019-03-29", "last_synced_at": "2026-10-11T16:14:55.220Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01656187" }, { "nct_id": "NCT01544998", "title": "Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Congestive Heart Failure" ], "interventions": [ { "name": "Nesiritide", "type": "DRUG" }, { "name": "Tadalafil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Saline load", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "21 Years to 90 Years" }, "enrollment_count": 43, "start_date": "2012-02", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-03-22", "last_synced_at": "2026-10-11T16:14:55.220Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01544998" }, { "nct_id": "NCT03199885", "title": "Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Adenocarcinoma", "Metastatic HER2-Positive Breast Carcinoma", "Recurrent Breast Adenocarcinoma", "Recurrent HER2-Positive Breast Carcinoma", "Stage III Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Unresectable Breast Carcinoma", "Unresectable HER2-Positive Breast Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2019-04-05", "completion_date": "2025-04-04", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-11T16:14:55.220Z", "location_count": 662, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03199885" }, { "nct_id": "NCT03187795", "title": "Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Spinal Cord Injuries", "Urinary Bladder, Neurogenic" ], "interventions": [ { "name": "Oxybutynin Chloride IR", "type": "DRUG" }, { "name": "Mirabegron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kessler Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 62, "start_date": "2019-04-03", "completion_date": "2022-03-30", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-11T16:14:55.220Z", "location_count": 1, "location_summary": "West Orange, New Jersey", "locations": [ { "city": "West Orange", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03187795" }, { "nct_id": "NCT06721884", "title": "Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Intestinal Bacterial Overgrowth Syndrome (SIBO)" ], "interventions": [ { "name": "Artemisia Annua Leaf", "type": "DIETARY_SUPPLEMENT" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "National University of Natural Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2025-01-01", "completion_date": "2026-01", "has_results": false, "last_update_posted_date": "2025-06-04", "last_synced_at": "2026-10-11T16:14:55.220Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06721884" }, { "nct_id": "NCT00621777", "title": "A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder", "Bipolar Disorder", "Smoking" ], "interventions": [ { "name": "Varenicline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 247, "start_date": "2008-02", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2017-12-21", "last_synced_at": "2026-10-11T16:14:55.220Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Bloomington, Indiana • Boston, Massachusetts + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00621777" }, { "nct_id": "NCT01994525", "title": "Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malaria" ], "interventions": [ { "name": "PfRAS", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Challenge", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 54, "start_date": "2014-01-24", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2019-09-17", "last_synced_at": "2026-10-11T16:14:55.220Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01994525" } ] }